Imfinzi delivers sustained OS benefit in final analysis of CASPIAN trial

This article was originally published here

Imfinzi gave the desired result for the company through its combination with a choice of standard-of-care (SoC) chemotherapies in the first line setting in patients with the lung

The post Imfinzi delivers sustained OS benefit in final analysis of CASPIAN trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply